Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy
SENSOR enrolled patients with CML without MMR after ≥18 months of imatinib. At 12 months after switch to nilotinib, 51.1% of patients achieved MMR. BIM polymorphisms did not affect MMR achievement after switch to nilotinib. Nilotinib provided benefit to patients with suboptimal response to imatinib.